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Abstract
Background: Combined heart and renal failure is associated with high cardiovascular morbidity and mortality. Anti-oxidant
and anti-inflammatory, non-hematopoietic effects of erythropoietin (EPO) treatment have been proposed. Monocytes may
act as biosensors of the systemic environment. We hypothesized that monocyte transcriptomes of patients with cardiorenal
syndrome (CRS) reflect the pathophysiology of the CRS and respond to short-term EPO treatment at a recommended dose
for treatment of renal anemia.
Methods: Patients with CRS and anemia (n = 18) included in the EPOCARES trial were matched to healthy controls (n = 12).
Patients were randomized to receive 50 IU/kg/week EPO or not. RNA from CD14+-monocytes was subjected to genome
wide expression analysis (Illumina) at baseline and 18 days (3 EPO injections) after enrolment. Transcriptomes from patients
were compared to healthy controls and effect of EPO treatment was evaluated within patients.
Results: In CRS patients, expression of 471 genes, including inflammation and oxidative stress related genes was different
from healthy controls. Cluster analysis did not separate patients from healthy controls. The 6 patients with the highest
hsCRP levels had more differentially expressed genes than the 6 patients with the lowest hsCRP levels. Analysis of the
variation in log2 ratios of all individual 18 patients indicated that 4 of the 18 patients were different from the controls,
whereas the other 14 were quite similar. After short-term EPO treatment, every patient clustered to his or her own baseline
transcriptome. Two week EPO administration only marginally affected expression profiles on average, however, individual
gene responses were variable.
Conclusions: In stable, treated CRS patients with mild anemia, monocyte transcriptomes were modestly altered, and
indicated imprints of inflammation and oxidative stress. EPO treatment with a fixed dose has hematopoietic effects, had no
appreciable beneficial actions on monocyte transcription profiles, however, could also not be associated with undesirable
transcriptional responses.
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Introduction
Patients suffering from chronic heart failure (CHF) and
concomitant renal failure have increased cardiovascular morbidity
and mortality [1]. Conversely, chronic kidney disease (CKD)
patients have an increased risk for myocardial infarction with
higher mortality compared to the general population [2]. This
condition in which combined cardiac and renal dysfunction
aggravates failure of the individual organs has been described as
the cardiorenal syndrome (CRS) [3]. In this paper, CRS is defined
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as the combination of CHF and CKD. Among the pathways
involved in the pathogenesis of CRS are oxidative stress,
inflammation, the renin-angiotensin system (RAS) and the
sympathetic nervous system (SNS), the cardiorenal connectors [3].
Anemia is a well-recognized problem in chronic renal disease.
The pathophysiology of renal anemia includes an absolute and/or
relative deficiency to erythropoietin (EPO) and a reduced
sensitivity to EPO of red-cell lineages. Regarding the former,
analogues of the human EPO are available to increase EPO levels.
Regarding the latter, transferrin receptor-bound polymeric IgA1
was recently identified as an important modulator of the bone
marrow response to EPO [4]. Besides the cells involved in
erythropoiesis, a number of other cells involved in cardiovascular
disease have been shown to express EPO receptors (reviewed in
[5]) including monocytes [6].
Anemia can aggravate heart and renal failure and is associated
with worse outcome in CHF [7] and CKD [8]. EPO can be used
to treat renal anemia, however, normalization of hemoglobin
(Hgb) in CKD patients is not associated with improved
cardiovascular outcome [9,10,11]. In contrast, high EPO doses
and the inability to reach target Hgb seem to be associated with
adverse outcome [12]. EPO also has non-hematopoietic, anti-
inflammatory and anti-oxidative effects on kidneys, brain, heart
and vasculature [13,14]. Nonetheless, not all reports are equivocal,
and undesirable actions such as oxidative stress have also been
reported [5].
Among several other circulating cells, monocytes can be used as
sensors for direct EPO effects on these cells or for indirect actions
of EPO by affecting the internal environment. Monocytes have
previously been shown to be able to serve as biosensors to detect
changes in the systemic environment [15] and to evaluate the
response to treatment [16,17]. In addition, monocytes are key
players in the initiation and progression of atherosclerosis.
Monocytes have shown to be sensitive to several of the cardiorenal
connectors, such as cytokines and angiotensin II [18,19]. We have
recently described that monocytes from CKD patients display
increased expression of genes coding for suppressors of cytokine
signaling proteins [20,21]. Monocyte transcriptomes also corre-
lated with collateral artery formation in patients with coronary
artery disease [22].
We have previously shown that short-term, low dose EPO
treatment increases erythropoiesis as detected by increased
reticulocyte counts [24]. In the present study, it was investigated
whether monocyte gene expression profiles of cardiorenal patients
reflect the altered systemic environment in CRS and are
responsive to short-term, low-dose EPO treatment. First, we
explored whether monocytes of CRS patients indeed display
altered gene expression profiles compared to healthy controls.
Moreover, we investigated whether short-term EPO treatment
affects monocyte gene transcription. Since EPO might have
undesirable effects, both potentially beneficial effects of EPO, such
as induction of anti-inflammatory and anti-oxidant genes and
potential detrimental effects on monocyte transcriptomes were
investigated.
Methods
Study design
The present study is part of the EPOCARES trial (Clinical-
Trials.gov, NCT00356733), in which CRS patients on regular
treatment and standardized iron supplementation were random-
ized to receive fixed dose subcutaneous EPO treatment or no EPO
treatment. Details of the study design have previously been
described [23,24]. Matched for age and gender, we selected 18
patients with mild anemia (10.3–11.9 g/dl in women and 10.3–
12.6 g/dl in men), moderate renal failure (estimated creatinine
clearance 20–70 ml/min calculated by Cockcroft-Gault formula)
and CHF. CHF was defined as New York Heart Association class
II-IV, based on symptoms, signs and objective abnormality on
echocardiography [25]. Patients were included with reduced
ejection fraction (,50%) or left ventricular end diastolic volume
index ,97 ml/m2 with evidence of diastolic left ventricular
dysfunction [26]. The medical ethics committee of the Univ.
Medical Center Utrecht, The Netherlands approved the protocol
and all patients gave their written informed consent. All
procedures were in accordance with the Helsinki Declaration.
After enrolment, 12 out of 18 patients were randomized to
receive a low dose of Epoetin-b therapy (50 IU/kg/wk; Neor-
ecormon, Roche Pharmaceuticals). Dosages of EPO used in
cardio- and cerebro-protection are higher than the dosages
normally used for the treatment of renal anemia. It should also
be remarked, that despite the desire to study higher doses of EPO
in this setting, this would not be justifiable, given the data that is
out there to suggest that the higher dosages may be associated
unwanted cardiovascular effects [9,11,27]. Biochemical analysis
and monocyte isolation for gene expression analyses were
performed at baseline and after 18 days of EPO treatment (i.e.
after 3 EPO injections), prior to the expected rise in Hgb level.
Twelve healthy age- and gender-matched persons served as
baseline controls.
Sample collection and microarray procedures
Peripheral blood was collected from patients and healthy
controls in EDTA containing tubes after 30 minutes in a resting
position. Blood was kept on ice. Within 3 hours of blood
withdrawal, CD14+-monocytes were positively isolated with the
use of immunomagnetic beads (Invitrogen, CA). The purity of the
isolated monocyte population was on average 90% as determined
by CD14+-staining on flow cytometry analysis.
mRNA was isolated from cell collections using Trizol reagent
(Invitrogen/Gibco, CA) according to the manufacturer’s instruc-
tion. Subsequently, mRNA was purified with NucleoSpinH RNAII
(Macherey-Nagel, Du¨ren, Germany) and samples were sent to
ServiceXS (Leiden, The Netherlands) for further microarray
processing. In brief, quality and integrity of RNA was checked by
lab-on-chip technology (Bioanalyzer Agilent, CA). Subsequently,
Illumina TotalPrep RNA Amplificationkit (Applied Biosystems/
Ambion, TX) was used to create double-stranded cDNA from
500 ng total RNA. After cDNA purification, in vitro transcription
reaction resulted in aRNA, which was also purified. Amplified
biotinylated aRNA was finally randomly hybridized to Human-
Ref-8 V3.0 Expression BeadChips (Illumina, CA), followed by
scanning for raw gene expression intensities on Illumina’s
BeadArray scanner.
Validation of gene array results by real-time quantitative
polymerase chain reaction (qPCR)
Monocyte cDNA samples from all patients before and after 18
days EPO treatment and from healthy controls were subjected to
real-time qPCR by BioMark dynamic array technology (Fluidigm,
CA), performed at ServiceXS. The cDNA samples were exposed
to specific target amplification, using PreAmp Master Mix and
Gene Expression Assays (Taqman; Applied Biosystems, TX) for
IL8, FOS, EGR1, CX3CR1, ADRB2, EPO-R and housekeeping
genes GAPDH, 18S, b-Actin and RPL13a. They were subjected
to a BioMark dynamic array for determination of Ct-values. Each
gene was measured in triplicate for each sample. The default
Monocyte Transcriptomes in Cardiorenal Syndrome
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Taqman PCR protocol was used with an annealing temperature of
60uC and a total of 35 cycles of PCR.
Statistical analyses
Clinical characteristics are presented as mean6standard devi-
ation or median (interquartile range) for respectively normally and
not normally distributed data. Analysis between groups for
statistically significant differences was performed by Student’s t-
test, Mann-Whitney U test or paired analysis when appropriate. P-
values,0.05 were considered significant.
For microarray data analysis, individual bead outliers were
removed from raw bead data if signal intensity was higher or lower
than median intensity plus or minus 26median absolute deviation
respectively (T4Illumina, software developed by the authors). The
transcript level of a gene in each sample was considered present
when the average raw intensity of the gene was significantly higher
than negative controls from the same BeadArray (t-test; T4Illu-
mina). Genes were significantly present (transcriptionally active) in
a group when present in at least 8 or 13 out of 12 or 18,
respectively (based on group size by Z-test, SigmaStat). After
normalization procedure (Log2-Quantile; FlexArray version 1.6
[28]), differential expression of a gene between two groups was
tested by unpaired Cyber t-test for the comparison between groups
at baseline and paired t-test for the comparison between patients at
baseline and after two weeks of EPO treatment [29]. A. P-
value,0.05 was considered significant. To investigate the effects of
EOP, genes that were significantly differentially expressed were
analyzed by hierarchical clustering, with Euclidean distance as a
similarity measure and clustering was based on average-linkage
correlation (Multi-experiment-Viewer, MeV, version 4.8 [30]). To
construct the heat-map, relative expression levels for each gene
and each individual were calculated as a ratio between the actual
signal for that gene and the average signal for that gene at
baseline. Common oxidative stress-, inflammation- and RAS-
related genes were specifically addressed to search for differences
between healthy controls and patients, and for the effect of short-
term EPO treatment in patients. Moreover, because of the
relevance of inflammation for monocyte function, we subdivided
the group of patients into three tertiles of CRP levels and
investigated whether CRP levels were associated with different
transcriptomes at baseline by comparing the lowest and highest
tertiles. Finally, variation in the normally distributed log2 ratios of
each of the patients’ baseline datasets was individually compared
to variation of the control datasets. This provided further insight in
the homogeneity of the baselines samples.
For real-time qPCR analysis, software version 2.0.6 was used for
Ct determination from the reaction chambers on the array. Linear
baseline correction was applied and the Ct threshold method
selected was ‘Auto (Global)’. Average Ct values per gene for each
sample were calculated for data that passed amplification curve
quality thresholds (default value 0.65). GAPDH served as
housekeeping gene, since this gene was considered most stable
when comparing 18S, b-Actin, RPL13a and GAPDH in both
NormFinder and GeNorm. Normalized gene expression (Ct gene
of interest–Ct GAPDH; DCt) was related to normalized gene
expression in the reference group (DDCt). Fold changes were
calculated by 22DDCT [20,21]. Gene expression differences
between healthy controls and patients, and effects of EPO
treatment were tested by Student’s t-test and paired analyses
respectively. P-value,0.05 was considered significant.
Accession codes
The data discussed in this publication have been deposited in
MIAME compliant NCBI’s Gene Expression Omnibus [31] and
are accessible through GEO Series accession number GSE17582
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17582).
Results
Study population characteristics
Baseline characteristics of patients with CRS and anemia and
age- and gender-matched controls are described in table 1. After
the baseline measurement, twelve out of 18 patients were started
on EPO treatment. After 18 days, Hgb was not increased
significantly compared to baseline (delta Hgb 0.561.0 g/dl in
EPO-treated group vs.20.461.0 g/dl in non EPO-treated group;
p = 0.133). The short-term EPO treatment did trigger the
hematopoietic system as indicated by increased reticulocyte counts
(0.0560.02 vs. 0.0760.02610e12/l; p,0.001). Whole blood
mononuclear cell (MNC) counts were not different in patients
compared to healthy controls (6.3(3.2) vs. 5.1(2.0)6106 MNC/ml
whole blood; p = 0.215) and remained unchanged after short-term
EPO treatment (6.3(3.2) vs. 6.8(2.7)6106 MNC/ml whole blood;
p = 0.420).
Erythropoietin receptor expression on monocytes
All monocyte samples showed a significant gene expression of
the EPO receptor (EPO-R), reflected by Ct values of 18.060.5 on
real-time qPCR. Slightly higher EPO-R gene expression was
Table 1. Baseline characteristics.
Healthy
controls Patients P-value
(n =12) (n=18)
Age (years) 68612 70611 N.S.
Male gender (%) 8 (67%) 12 (67%) N.S.
Body mass index (kg/m2) 23.761.9 26.764.5 0.019
Estimated creatinine
clearance (ml/min)
69619 36611 ,0.001
Hemoglobin (g/dl) 14.060.8 11.860.9 ,0.001
Total cholesterol (mmol/l) 5.0861.26 4.3961.52 N.S.
HDL (mmol/l) 1.3960.37 1.2160.29 N.S.
LDL (mmol/l) 3.3161.07 2.3861.17 0.039
Triglycerides (mmol/l) 0.8460.50 1.7561.70 N.S.
hsCRP (mg/l) 1.0 (0.8) 4.0 (8.0) 0.007
Ejection fraction (%) - 4664
Systolic blood pressure (mmHg) 129624 129618 N.S.
Diastolic blood pressure (mmHg) 8167 7068 0.001
Diabetes Mellitus (%) - 6 (33%)
Smoking (%) 2 (17%) 3 (17%) N.S.
Medication
- Acetylsalicylic acid (%) - 8 (44%)
- Statin (%) - 10 (56%)
- Angiotensin blockade (ACEi/ARB)
(%)
- 16 (89%)
-b-blockade (%) - 13 (72%)
- Spironolactone (%) - 4 (22%)
Values are expressed as mean 6 SD, number (percentage) or median
(interquartile range).
hsCRP: high sensitive C-reactive protein; ACEi: angiotension-converting enzyme
inhibitor; ARB: angiotensin II receptor blocker; N.S. not significant.
doi:10.1371/journal.pone.0041339.t001
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found in patients compared to controls (fold change 1.2; p = 0.05).
EPO treatment for 18 days did not significantly alter EPO-R
expression (fold change 1.0).
Monocyte gene expression profile in cardiorenal
syndrome patients compared to healthy controls
Global gene expression profile changes, hierarchical
clustering. We compared monocyte gene expression profiles
of CRS patients (n = 18) and healthy controls (n = 12) at baseline.
Out of 25,528 genes explored, signals of 12,165 exceeded
background in at least one of the two groups; 471 genes were
differentially expressed in CRS patients vs. healthy controls (p-
value,0.05; 1.8% of total assessed genes). Correction for multiple
testing, for example by applying FDR, was not performed because
of the very small sample size. Fold changes were low, ranging from
0.3–1.7. Cluster analysis of differentially expressed genes did not
separate patients from controls. Clustering of genes could also not
be explained by gender or age of the investigated subjects.
Specific gene expression changes. In CRS patients, 214
genes displayed increased and 257 decreased expression compared to
healthy controls. Table 2 gives an overview of the 15 most induced
and downregulated genes for this comparison. A table with all genes
with changed expression can be found in table S1. Patients showed
lower expression of the transcription factors EGR1 and FOS.
Furthermore, patients showed decreased expression of hemoglobin-
related genes HBA2 and HBB compared to healthy controls.
Additional experiments with extra washing steps of isolated monocyte
samples suggest that expression of these two genes could possibly be
attributed to reticulocyte contamination (data not shown).
We specifically addressed whether inflammation and oxidative
stress in CRS patients were reflected by monocyte gene
expressions. Several interesting genes involved in inflammation
(i.e. IL8, IL17, IL1RAP, CX3CR1, and several TLRs) and
oxidative stress (i.e. DUSP1, GPX3, DHRS9) were indeed
modulated in CRS patients (table 3, and table S2 for the entire
panel of genes). Remarkably, some of these genes exert pro- and
others anti-stimulating activities. With regard to SNS, only
ADRB2 was induced in patients. Differential expression of IL8,
FOS, EGR1, CX3CR1 and ADRB2 was confirmed by qPCR
(figure 1).
Subanalysis with respect to CRP. After dividing the 18
patients in three groups, we compared the 6 patients with the
lowest CRP levels with the patients with highest CRP levels; the
middle tertile was left out of the comparison. This subanalysis
confirmed that CRP does influence monocyte transcriptomes
(table 4). The group sizes become too small for a detailed
comparison.
Subanalysis with respect to individual variation in gene
expression of the cardiorenal patients at baseline. Because
of the relatively limited differential expression at baseline, we
analyzed the homogeneity of the baseline samples of the CRS
patients compared to the controls by comparing the standard
deviation of the log2 ratios. Indeed, 4 out of the 18 patients showed
substantial variation in log2 ratios whereas the other did show
minimal variation. The number was too small to investigate
whether the response to EPO of these 4 patients was different from
the 14 other patients.
Monocyte gene expression in cardiorenal syndrome
patients after 18 days of currently recommended dose
erythropoietin treatment
Global gene expression profile changes, hierarchical
clustering. The effect of 18 days EPO treatment was assessed
in the 12 CRS patients before and after the initiation of EPO
treatment. Out of 25,528 genes explored, signals of 12,198 genes
exceeded background in the monocyte transcriptome before and/
or after treatment. Of these, 399 genes were significantly
differentially modulated by EPO (p-value,0.05; 1.5% of total
assessed genes; see table S3). Fold changes were low in this
comparison (range 0.58–3.49); differential modulation of 211
genes was .1.10 or ,0.90 fold. Strikingly, Euclidean clustering
with these genes demonstrated that treated patient clustered close
to his/her own baseline gene profile (figure 2 and figure S1).
Although our intervention study was not designed to that purpose.
clustering of patients did not seem to be associated with age,
gender, or the presence of diabetes.
Specific gene expression changes. The 3 EPO injections
only increased HBB and HBA2 expressions significantly with a
fold change.1.35 when comparing group mean gene intensities.
As mentioned, expression of these two genes may be attributed to
reticulocyte contamination. Subsequently, to evaluate if short-term
EPO treatment demonstrated monocyte gene modulations with
regard to inflammation or oxidative stress we assessed gene
expression changes in selected gene panels. None of the genes were
differentially expressed with a p-value,0.05 (table S4).
Individual gene response to erythropoietin. Since the
expression profile of the treated group did not substantially differ
from baseline, we compared gene expression modulations in the
twelve individual patients. The individual gene response to EPO
was remarkably variable in all patients. Only two genes (HBB,
HBA2) were induced and one gene downregulated (RAMP2) in
more than two patients after treatment.
Discussion
The present study is based on three of our recent studies in
humans. The first showed altered leukocyte gene expression in
untreated hypertensive patients, which was strongly attenuated in
matched, well-treated patients [16]. In the other two papers,
monocytes gene expressions in CKD [20] and end-stage renal
disease [21] patients showed induction of the so-called suppressors
of cytokine signaling, which modulate the Jak/Stat transcription
pathway and steer the actions of IFNc and IL6 [32]. Therefore,
we hypothesized that monocytes, as cells involved in atheroscle-
rosis [15,33], could function as biosensors of the systemic
environment of CRS patients with anemia and of the effects of
short-term EPO treatment.
When comparing monocyte transcriptomes in CRS patients to
healthy controls, one of the most remarkable observations is the
limited number of changes, which could have a number of
potential explanations. First, the study subjects were carefully
selected, stable cardiorenal failure patients; the regular treatment,
including angiotensin blockade (89%), statins (56%), acetylsalicylic
acid (44%) and b-blockers (72%) may have dampened gene
expression changes, even though the inflammatory environment
was not completely normalized as judged from increased hsCRP
levels. In this regard, monocytes displayed slightly higher numbers
of genes with modulated expression in subjects with higher CRP
values, than in subjects with lower CRP values. Unfortunately, the
sample size is too small and the percentage of patients on
medication too high to separate out the influence of any of the
individual drugs. Second, it may be that the monocyte has adapted
to the continuous exposure of stimuli, e.g. inflammation and
oxidative stress. However, if this were the case, we would expect to
see more ‘imprints’ of such adaptations in the transcriptome (e.g.
more pronounced induction of anti-oxidant genes). Third, critical
changes in monocytes of cardiorenal patients may be not achieved
Monocyte Transcriptomes in Cardiorenal Syndrome
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at the level of gene transcription but at the level of protein
synthesis, modification and trafficking. It is unlikely that the choice
of Illumina arrays underlies the paucity of changes, since this
platform provided highly reproducible results and revealed
important biological processes in monocytes [34]. In our own
laboratory, the same platform yielded very strong transcriptional
responses of endothelial cells in culture to IFNc and IL6 [35].
Regarding the methodology applied in the present study, we did
not correct for multiple testing using methods such as FDR,
because of the small sample size. Therefore, the possibility exists
that some of the reported changes in expression could be false
positives. In another EPOCARES sub-study, which evaluated the
responses of plasma hepcidin to the same short-term low dose
EPO stimulation [24], we found clear responses in plasma
hepcidin levels and reticulocyte numbers, clearly indicating that
the dose of EPO was sufficiently strong to appreciably affect iron
metabolism and erythropoiesis [23]. A last explanation is that the
group is quite heterogeneous, as exemplified by the analysis of
variation in log2 values of each patient.
The pathophysiology of CRS is complex and likely involves
disruption of the pro-/anti-inflammatory and pro-/anti-oxidant
balance, and enhanced activity of the SNS. We investigated
whether monocytes reveal imprints of such alterations. Earlier
studies in our group reported modulated expression of SOCS
genes in monocytes of CKD patients [20]. We found increased
CX3CR1 expression in CRS patients. CX3CR1 binds fractalkine
(CX3CL1), a CX3C chemokine, which is expressed by activated
endothelial cells and mediates adhesion and chemotaxis of
CX3CR1 expressing monocytes and accumulation of macrophag-
es in atherosclerotic lesions [36]. Transcription of some genes that
stimulate inflammation (e.g. IL8, IL1RAP) was decreased in CRS
patients compared to healthy controls, which may indicate
negative feedback in response to inflammation. All-in-all, our
analysis does not point to the cytokines IL6, IFNc and TNFa, that
have classically been associated with low grade inflammation in
Table 2. Top 15 of induced and downregulated genes in CRS patients vs. healthy controls.
UPREGULATED (ranked by descending fold change)
Accession Number Symbol Description Fold change P-value
NM_018487.2 HCA112 Transmembrane protein 176A 1.695 0.037
NM_012456.1 TIMM10 Translocase of inner mitochondrial membrane 10 homolog 1.591 ,0.0001
NM_017911.1 C22ORF8 Family with sequence similarity 118, member A 1.582 0.012
NM_001337.3 CX3CR1 Chemokine (C-X3-C motif) receptor 1 1.491 ,0.0001
NM_006498.2 LGALS2 Lectin, galactoside-binding, soluble, 2 1.464 0.028
NM_000024.3 ADRB2 Adrenergic, b2-, receptor, surface 1.446 0.002
NM_005771.3 DHRS9 Dehydrogenase/reductase (SDR family) member 9 1.434 0.008
NM_198097.1 C7ORF28B Chromosome 7 open reading frame 28B 1.428 0.005
NM_001343.1 DAB2 Disabled homolog 2, mitogen-responsive phosphoprotein 1.425 ,0.001
NM_016021.2 UBE2J1 Ubiquitin-conjugating enzyme E2, J1 1.424 ,0.001
NM_030670.1 PTPRO Protein tyrosine phosphatase, receptor type, variant 6 1.385 ,0.0001
NM_001008566.1 TPST2 Tyrosylprotein sulfotransferase 2 1.379 0.001
NM_030671.1 PTPRO Protein tyrosine phosphatase, receptor type, variant 5 1.372 ,0.001
NR_003038.1 SNHG5 Small nucleolar RNA host gene 5 1.359 0.037
NM_080914.1 ASGR2 asialoglycoprotein receptor 2 1.358 0.003
DOWNREGULATED (ranked by ascending fold change)
NM_000518.4 HBB Hemoglobin, b 0.297 0.001
NM_000517.3 HBA2 Hemoglobin, a2 0.376 0.003
XM_936120.1 HLA-DQA1 PREDICTED: major histocompatibility complex, class II 0.474 0.006
NM_000584.2 IL8 Interleukin 8 0.584 ,0.001
NM_005252.2 FOS V-fos FBJ murine osteosarcoma viral oncogene homolog 0.606 0.012
NM_006732.1 FOSB FBJ murine osteosarcoma viral oncogene homolog B 0.608 ,0.0001
NM_001964.2 EGR1 Early growth response 1 0.646 0.008
NM_004417.2 DUSP1 Dual specificity phosphatase 1 0.678 0.003
NM_004666.1 VNN1 Vanin 1 0.680 0.003
NM_024933.2 FLJ12056 Ankyrin repeat domain 53 0.692 0.012
NM_005502.2 ABCA1 ATP-binding cassette, sub-family A, member 1 0.707 0.009
NM_020152.2 C21ORF7 Chromosome 21 open reading frame 7 0.710 0.009
NM_017933.3 FLJ20701 Phosphotyrosine interaction domain containing 1 0.725 ,0.001
NM_002612.2 PDK4 Pyruvate dehydrogenase kinase, isozyme 4 0.736 0.017
NM_021732.1 AVPI1 Arginine vasopressin-induced 1 0.737 0.006
doi:10.1371/journal.pone.0041339.t002
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cardiovascular disease [37] and renal failure [38]. Nevertheless,
the transcriptome seemed to be responsive to the level of
inflammation, since higher CRP levels were associated with more
changes in monocyte gene expression.
Considering the pro/anti-oxidant balance in CRS patients,
expression changes were modest. Downregulation of genes
encoding for proteins with anti-oxidative action is suggested (e.g.
GPX3, PRDX3), though others were induced (DHRS9). De-
creased expression of oxidative stress responsive gene DUSP1 and
markers of early activation FOS and EGR1 possibly reflects
downregulation of gene expression in activated cells from our
patients. This phenomenon has been reported previously in
patients with coronary artery disease [39].
The only change in CRS patients related to the SNS was
increased expression of ADRB2, the adrenergic receptor b2
subtype that binds epinephrine and norepinephrine [40]. This
gene is involved in coupling the SNS to immune cell function [41].
Sympathetic hyperactivity is present in patients with heart [42]
and failure [43]. It was expected that chronic sympathetic
hyperactivity would lead to downregulation of adrenoceptor
density [44], which underlies the decrease in b-adrenoreceptor-
mediated responsiveness characteristic [45,46]. However, b-
blockade was previously shown to increase adrenoreceptor density
in leukocytes. Patients with the highest catecholamine levels had
the greatest rise in receptor density following b-blockade [44].
Albeit speculative, since 72% of our patients received b-blockade,
higher ADRB2 expression levels may indicate higher baseline
sympathetic activity compared to our healthy controls.
Our second aim was to evaluate short-term treatment with a
currently recommended EPO dose for renal anemia in this patient
Table 3. Induction and downregulation of oxidative stress and inflammation related genes in CRS patients vs. healthy controls.
Transcript Symbol Definition Fold change P-value
INFLAMMATION RELATED GENES
Cytokines and cytokine receptors
NM_000628.3 IL10RB Interleukin 10 receptor 1.15 0.044
NM_005535.1 IL12RB1 Interleukin 12 receptor, b1 1.10 0.006
NM_001560.2 IL13RA1 Interleukin 13 receptor, a1 1.15 0.037
NM_014339.3 IL17R Interleukin 17 receptor 1.19 0.012
NM_004633.3 IL1R2 Interleukin 1 receptor, type II 0.83 0.044
NM_002182.2 IL1RAP Interleukin 1 receptor accessory protein 0.89 0.017
NM_173842.1 IL1RN Interleukin 1 receptor antagonist 0.94 0.052
NM_181078.1 IL21R Interleukin 21 receptor 1.10 0.066
NM_004843.2 IL27RA Interleukin 27 receptor, a 1.22 0.001
NM_000584.2 IL8 Interleukin 8 0.58 0.001
NM_001557.2 IL8RB Interleukin 8 receptor, b 0.87 0.079
Chemokines and chemokine receptors
NM_002982.3 CCL2 Chemokine (C-C motif) ligand 2 0.77 0.008
NM_002983.1 CCL3 Chemokine (C-C motif) ligand 3 0.86 0.027
NM_001001437.3 CCL3L3 Chemokine (C-C motif) ligand 3-like 3 0.77 0.019
NM_001337.3 CX3CR1 Chemokine (C-X3-C motif) receptor 1 1.49 ,0.001
Inflammatory response
NM_003264.3 TLR2 Toll-like receptor 2 1.16 0.015
NM_006068.2 TLR6 Toll-like receptor 6 1.09 0.021
NM_016562.3 TLR7 Toll-like receptor 7 1.20 0.040
Interferon transcriptional regulation
NM_002200.3 IRF5 Interferon regulatory factor 5 1.44 0.051
OXIDATIVE STRESS RELATED GENES
Antioxidants
NM_002084.2 GPX3 Glutathione peroxidase 3 0.88 0.017
NM_006793.2 PRDX3 Peroxiredoxin 3 0.85 0.061
NM_203472.1 SELS Selenoprotein S 0.94 0.060
NM_005771.3 DHRS9 Dehydrogenase/reductase (SDR family) member 9 1.33 0.006
Genes involved in ROS metabolism
NM_024505.2 NOX5 NADPH oxidase, EF-hand calcium binding domain 5 1.05 0.052
NM_001141.1 ALOX15B Arachidonate 15-lipoxygenase, second type 0.93 0.084
NM_004417.2 DUSP1 Dual specificity phosphatase 1 0.68 0.003
doi:10.1371/journal.pone.0041339.t003
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population. In another arm of this study, there was a clear
decrease in hepcidin, an increase in reticulocytes, an increase in
serum transferrin receptor and in iron saturation [24] after 2
weeks of EPO. At 26 weeks, all of the patients except for 2 had a
clear increase in haemoglobin levels [47], and/or had been
subjected to phlebotomy (this is in the group in which in the longer
run, Hgb levels were kept stable by phlebotomy). We postulated
previously that EPO may dampen activated inflammatory and
oxidative stress systems in CRS patients [5]. By evaluating
transcriptomes after 18 days of EPO therapy, direct effects of
EPO should be discriminated from hematopoietic effects. How-
ever, EPO treatment did not substantially modulate the monocyte
transcriptome in our study. The transcriptome after short-term
EPO therapy closely clustered with to the baseline expression
profile for every patient in our cluster analysis. This suggests that
individual differences overrule the direct, short-term effects of
EPO. Furthermore, we found a highly variable gene expression
response to EPO in all patients, which hampers the detection of
group differences. The finding that EPO response at gene
expression level is so diverse may point at the variable clinical
response to EPO.
Several reasons may underlie the unexpected lack in differential
gene expression in response to EPO treatment. First, it was
remarkable that individual responses to EPO were so variable,
which hinders detection of global gene expression changes
between groups. Despite careful selection of patients and optimally
standardizing medical treatment, individual variations still seem to
dominate the effect of EPO therapy. Microarray technology has
shown to reflect the clinical response to medical therapy [16,17].
Our study certainly does not rule out that transcriptome analysis
on circulating cells could be applied to monitor early responses to
EPO, however, another cell type may better reflect the changes
induces by EPO [15]. One could think of endothelial progenitor
cells, that might better reflect the response of a target tissue to
EPO, or reticulocytes, that might better reflect the response of the
bone marrow to EPO. Studying targets organ cells per se
obviously is more invasive. Second, the dose and duration of
EPO treatment must be considered. Various animal studies have
shown protective effects of EPO in acute ischemia/reperfusion
injury of the heart and kidney [13,14]. EPO doses used in these
studies are considerably higher, ranging from 3000–5000 U/kg,
which is much higher than the dosages usually applied in CKD
and end-stage renal disease patients. However, recent evidence
from the CHOIR study shows that chronic administration of high
EPO dose (mean dose 11215 IU/wk) is associated with adverse
clinical events. Since we treat our patients up to 1 year, we chose a
currently recommended dose for the treatment of renal anemia of
50 IU/kg/wk (i.e. approximately 3000 IU/wk), and not a short-
term high dose treatment. As alternative to the present design, that
aimed to study both short and long term effects of EPO which did
not justify using a higher dose, one could possibly safely study the
effect of one single dose of a higher concentration of EPO in
humans. Altogether, the present data do not support a beneficial
role for non-hematopoietic, short-term effects of low dose EPO.
More importantly, using monocyte transcriptomes, we were
unable to demonstrate any harmful effects.
In summary, we demonstrate that differences in the gene
expression of monocytes, being biosensors of the pro-atherogenic
environment and mediators of early atherosclerosis, are limited in
our study subjects. Nevertheless, the observed changes point at two
of the systems we have proposed as important connectors in
combined heart and renal failure, being inflammation and
Table 4. Number of differentially expressed genes at
different expression and significance levels in patients with
low CRP and high CRP compared to healthy controls at
baseline.
CRP Low Middle High
N= 6 6 6
CRP (average, min-max) 1.2 (1–3) 4.2 (3–6) 21.7 (7–53)
Differentially expressed
genes vs. controls
# of genes # of genes
P,0.05 717 771
P,0.01 125 192
P,0.001 17 25
P,0.0001 1 10
P,0.05 & FC,0.74 or .1.35 16 58
P,0.001 & FC,0.82 or .1.2 8 21
P,0.0001 & FC,0.91 or .1.1 1 10
doi:10.1371/journal.pone.0041339.t004
Figure 1. Validation of differentially expressed genes on microarray by quantitative polymerase chain reaction. *P-value,0.05 for
gene expression in patients at baseline vs. healthy controls as determined with qPCR technique; oP-value,0.05 for gene expression in patients at
baseline vs. healthy controls as determined with microarray technique. ADRB2 adrenergic receptor, b2; CX3CR1 chemokine (C-X3-C motif) receptor 1;
EGR1 early growth response 1; FOS FBJ murine osteosarcoma viral oncogene homolog; GPX3 glutathione peroxidase 3; IL8 interleukin 8; qPCR
quantitative polymerase chain reaction.
doi:10.1371/journal.pone.0041339.g001
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oxidative stress. We also demonstrate that in monocytes, response
in gene expression to short-term administration of the currently
recommended dose of EPO is very limited, indicating that a dose
that is commonly used to combat the EPO deficiency of renal
anemia does not exert important non-hematopoietic effects on this
pivotal cell. Fortunately, we also have been unable to identify any
undesirable effects of this widely applied dose of EPO. Further
studies are necessary to investigate whether other immune cells
involved in the inflammatory response and in atherosclerosis may
be more sensitive to this recommended dose of EPO and whether
higher doses of EPO as used in cardiovascular trials do affect
monocyte gene expression.
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